litlas
Log inCreate account

David P. Dearnaley

Active 1981–2025

Also published as
David P Dearnaley
171
Papers
32,825
Citations
100
h-index
171
i10-index

Citations

Citations per year for David P. Dearnaley1896: 1 citations1982: 1 citations1983: 5 citations1984: 4 citations1985: 8 citations1987: 3 citations1988: 1 citations1989: 1 citations1990: 3 citations1991: 10 citations1992: 8 citations1993: 10 citations1994: 16 citations1995: 15 citations1996: 18 citations1997: 29 citations1998: 27 citations1999: 41 citations2000: 40 citations2001: 76 citations2002: 71 citations2003: 78 citations2004: 64 citations2005: 89 citations2006: 89 citations2007: 111 citations2008: 126 citations2009: 178 citations2010: 228 citations2011: 285 citations2012: 225 citations2013: 272 citations2014: 249 citations2015: 243 citations2016: 233 citations2017: 207 citations2018: 322 citations2019: 891 citations2020: 923 citations2021: 886 citations2022: 638 citations2023: 449 citations2024: 715 citations2025: 350 citations2026: 17 citations1897–1981: no citations, so these years are not shown1986: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,499 citing papers, 21.9% of this breakdownUnited Kingdom: 1,283 citing papers, 11.2% of this breakdownCanada: 657 citing papers, 5.8% of this breakdownGermany: 629 citing papers, 5.5% of this breakdownItaly: 551 citing papers, 4.8% of this breakdownChina: 540 citing papers, 4.7% of this breakdownFrance: 534 citing papers, 4.7% of this breakdownNetherlands: 497 citing papers, 4.3% of this breakdownAustralia: 439 citing papers, 3.8% of this breakdownBelgium: 304 citing papers, 2.7% of this breakdownSpain: 302 citing papers, 2.6% of this breakdownSwitzerland: 292 citing papers, 2.6% of this breakdown
0%21.9%Other 25.4%

Institutions

Fields

  • Medicine74.5%
  • Biochemistry, Genetics and Molecular Biology13.7%
  • Physics and Astronomy5.3%
  • Computer Science1.5%
  • Immunology and Microbiology1%
  • Engineering0.9%
  • Other3.1%

Topics

  • Prostate Cancer Treatment and Research15.3%
  • Prostate Cancer Diagnosis and Treatment12.5%
  • Advanced Radiotherapy Techniques5.5%
  • Radiopharmaceutical Chemistry and Applications2.7%
  • Cancer, Lipids, and Metabolism2.4%
  • Cancer Genomics and Diagnostics1.8%
  • Other59.8%

Coauthors

All papers

Open in search
  1. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

    Authors: Nicholas D. James, Johann S. de Bono, Melissa Spears, Noel W. Clarke, Malcolm D. Mason, David P. Dearnaley, A.W.S. Ritchie, Claire Amos, Clare Gilson, Robert J. Jones, David Matheson, Robin Millman, Gerhardt Attard, Simon Chowdhury, William Cross, Silke Gillessen, Christopher Parker, John M. Russell, Dominik Berthold, Chris Brawley, F. Adab, San Aung, Alison Birtle, Jo Bowen, Susannah Brock, Prabir Chakraborti, Catherine Ferguson, Joanna Gale, Emma Gray, Mohan Hingorani, Peter Hoskin, J.F. Lester, Zafar Malik, Fiona McKinna, Neil McPhail, Julian Money‐Kyrle, Joe M. O’Sullivan, Omi Parikh, Andrew Protheroe, Angus Robinson, Narayanan Srihari, Carys Thomas, John Wagstaff, James Wylie, Anjali Zarkar, Mahesh Parmar, Matthew R. Sydes - New England Journal of Medicine 2017 cited by 1,772

  2. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

    Authors: Nicholas D. James, Matthew R. Sydes, Noel W. Clarke, Malcolm D. Mason, David P. Dearnaley, Melissa Spears, A.W.S. Ritchie, Christopher Parker, John M. Russell, Gerhardt Attard, Johann S. de Bono, William Cross, Robert J. Jones, George N. Thalmann, Claire Amos, David Matheson, Robin Millman, Mymoona Alzouebi, S. Beesley, Alison Birtle, Susannah Brock, Richard Cathomas, Prabir Chakraborti, Simon Chowdhury, Audrey Cook, Tony Elliott, Joanna Gale, Stephanie Gibbs, John D. Graham, John Hetherington, Robert Hughes, Robert Laing, Fiona McKinna, Duncan B. McLaren, Joe M. O’Sullivan, Omi Parikh, C. Peedell, Andrew Protheroe, Angus Robinson, Narayanan Srihari, Rajaguru Srinivasan, John Staffurth, Santhanam Sundar, Shaun Tolan, David Tsang, John Wagstaff, Mahesh Parmar - The Lancet 2015 cited by 1,968

  3. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

    Authors: Christopher Parker, Nicholas D. James, Chris Brawley, Noel W. Clarke, Alex Hoyle, Adnan Ali, A.W.S. Ritchie, Gerhardt Attard, Simon Chowdhury, William Cross, David P. Dearnaley, Silke Gillessen, Clare Gilson, Robert J. Jones, Ruth E. Langley, Zafar Malik, Malcolm D. Mason, David Matheson, Robin Millman, John M. Russell, George N. Thalmann, Claire Amos, Roberto Alonzi, Amit Bahl, Alison Birtle, Omar Din, Hassan Douis, Chinnamani Eswar, Joanna Gale, Melissa Gannon, Sai Jonnada, Sara Khaksar, J.F. Lester, Joe M. O’Sullivan, Omi Parikh, Ian Pedley, Delia Pudney, D.J. Sheehan, Narayanan Srihari, Anna Tran, Mahesh Parmar, Matthew R. Sydes - The Lancet 2018 cited by 1,262

  4. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

    Authors: David P. Dearnaley, Isabel Syndikus, Helen Mossop, Vincent Khoo, Alison Birtle, David Bloomfield, John D. Graham, Peter Kirkbride, John Logue, Zafar Malik, Julian Money‐Kyrle, Joe M. O’Sullivan, Miguel Panades, Chris Parker, Helen Patterson, Christopher Scrase, John Staffurth, Andrew Stockdale, Jean Tremlett, Margaret Bidmead, Helen Mayles, Olivia Naismith, C. South, Annie Gao, Clare Cruickshank, Shama Hassan, Julia Pugh, Clare Griffin, Emma Hall - The Lancet Oncology 2016 cited by 1,317

  5. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

    Authors: Gerhardt Attard, Laura Murphy, Noel W Clarke, William Cross, Robert J Jones, Christopher C Parker, Silke Gillessen, Adrian Cook, Chris Brawley, Claire L Amos, Nafisah Atako, Cheryl Pugh, Michelle Buckner, Simon Chowdhury, Zafar Malik, J Martin Russell, Clare Gilson, Hannah Rush, Jo Bowen, Anna Lydon, Ian Pedley, Joe M O'Sullivan, Alison Birtle, Joanna Gale, Narayanan Srihari, Carys Thomas, Jacob Tanguay, John Wagstaff, Prantik Das, Emma Gray, Mymoona Alzoueb, Omi Parikh, Angus Robinson, Isabel Syndikus, James Wylie, Anjali Zarkar, George Thalmann, Johann S de Bono, David P Dearnaley, Malcolm D Mason, Duncan Gilbert, Ruth E Langley, Robin Millman, David Matheson, Matthew R Sydes, Louise C Brown, Mahesh K B Parmar, Nicholas D James, Elin Jones, Katherine Hyde, Hilary Glen, Sarah Needleman, Ursula McGovern, Denise Sheehan, Sangeeta Paisey, Richard Shaffer, Mark Beresford, Zafar Malik, Anjali Zarkar, Emilio Porfiri, David Fackrell, Ling Lee, Thiagarajan Sreenivasan, Sue Brock, Simon Brown, Amit Bahl, Mike Smith-Howell, Cathryn Woodward, Mau-Don Phan, Danish Mazhar, Krishna Narahari, Jacob Tanguay, Fiona Douglas, Anil Kumar, Abdel Hamid, Azman Ibrahim, Dakshinamoorthy Muthukumar, Matthew Simms, Jane Worlding, Anna Tran, Mohammed Kagzi, Prantik Das, Carmel Pezaro, Virgil Sivoglo, Benjamin Masters, Pek Keng-Koh, Caroline Manetta, Duncan McLaren, Nishi Gupta, Denise Sheehan, Stergios Boussios, Henry Taylor, John Graham, Carla Perna, Lucinda Melcher, Warren Grant, Katherine Hyde, Ami Sabharwal, Uschi Hofmann, Robert Dealey and 73 more - The Lancet 2021 cited by 367

  6. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

    Authors: N.W. Clarke, Amin Ali, Fiona C. Ingleby, Alex Hoyle, Claire Amos, Gerhardt Attard, Chris Brawley, J. Calvert, S. Chowdhury, Audrey Cook, William Cross, David P. Dearnaley, Hassan Douis, Duncan C. Gilbert, Silke Gillessen, Robert J. Jones, Ruth E. Langley, Archie Macnair, Zafar Malik, Malcolm D. Mason, David Matheson, R. Millman, Chris Parker, A.W.S. Ritchie, Hannah Rush, John M. Russell, Janet E. Brown, S. Beesley, Alison Birtle, Lisa Capaldi, Joanna Gale, Stephanie Gibbs, Anna Lydon, Ashok Nikapota, Aurelius Omlin, Joe M. O’Sullivan, Omi Parikh, Andrew Protheroe, Sarah Rudman, Narayanan Srihari, Matthew Simms, Jacob Tanguay, Shaun Tolan, John Wagstaff, Jan Wallace, J. Wylie, Anjali Zarkar, Matthew R. Sydes, Mahesh Parmar, Nicholas D. James - Annals of Oncology 2019 cited by 398

  7. Microbiota- and Radiotherapy-Induced Gastrointestinal Side-Effects (MARS) Study: A Large Pilot Study of the Microbiome in Acute and Late-Radiation Enteropathy

    Authors: Miguel Reis Ferreira, Jervoise Andreyev, Kabir Mohammed, Lesley Truelove, Sharon Gowan, Jia Li, S. Gulliford, Julian R. Marchesi, David P. Dearnaley - Clinical Cancer Research 2019 cited by 195

  8. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

    Authors: Gerhardt Attard, Laura Murphy, Noel W. Clarke, Ashwin Sachdeva, Craig Jones, Alex Hoyle, William Cross, Robert J. Jones, Christopher Parker, Silke Gillessen, Adrian Cook, Chris Brawley, Clare Gilson, Hannah Rush, Hoda Abdel-Aty, Claire Amos, Claire Murphy, Simon Chowdhury, Zafar Malik, John M. Russell, Nazia Parkar, Cheryl Pugh, Carlos Díaz-Montaña, Carmel Pezaro, Warren Grant, Helen Saxby, Ian Pedley, Joe M. O’Sullivan, Alison Birtle, Joanna Gale, Narayanan Srihari, Carys Thomas, Jacob Tanguay, John Wagstaff, Prantik Das, Emma Gray, Mymoona Alzouebi, Omi Parikh, Angus Robinson, Amir Montazeri, James Wylie, Anjali Zarkar, Richard Cathomas, Michael D. Brown, Yatin Jain, David P. Dearnaley, Malcolm D. Mason, Duncan C. Gilbert, Ruth E. Langley, Robin Millman, David Matheson, Matthew R. Sydes, Louise Brown, Mahesh Parmar, Nicholas D. James, Elin Jones, Katherine Hyde, Hilary Glen, Sarah Needleman, Ursula McGovern, Denise Sheehan, Sangeeta Paisey, Richard Shaffer, Mark Beresford, Zafar Malik, Anjali Zarkar, Emilio Porfiri, David Fackrell, Ling Lee, Thiagarajan Sreenivasan, Sue Brock, Simon Brown, Amit Bahl, Mike Smith-Howell, Cathryn Woodward, Mau-Don Phan, Danish Mazhar, Krishna Narahari, Jacob Tanguay, Fiona Douglas, Anil Kumar, Abdel Hamid, Azman Ibrahim, D. Muthukumar, Matthew Simms, Jane Worlding, Anna Tran, M. Kagzi, Prantik Das, Carmel Pezaro, Virgil Sivoglo, Benjamin Masters, Pek Keng-Koh, Caroline Manetta, Duncan B. McLaren, Nishi Gupta, Denise Sheehan, Stergios Boussios, Henry M. Taylor, John D. Graham and 80 more - The Lancet Oncology 2023 cited by 102

  9. Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial

    Authors: Chris Parker, Nicholas D. James, Chris Brawley, Noel W. Clarke, Adnan Ali, Claire Amos, Gerhardt Attard, Simon Chowdhury, Adrian Cook, William Cross, David P. Dearnaley, Hassan Douis, Duncan C. Gilbert, Clare Gilson, Silke Gillessen, Alex Hoyle, Robert J. Jones, Ruth E. Langley, Zafar Malik, Malcolm D. Mason, David Matheson, Robin Millman, Mary Rauchenberger, Hannah Rush, Martin Russell, Hannah Sweeney, Amit Bahl, Alison Birtle, Lisa Capaldi, Omar Din, Daniel Ford, Joanna Gale, Ann Henry, Peter Hoskin, M. Kagzi, Anna Lydon, Joe M. O’Sullivan, Sangeeta Paisey, Omi Parikh, Delia Pudney, Vijay Ramani, Peter Robson, Narayanan Srihari, Jacob Tanguay, Mahesh Parmar, Matthew R. Sydes, for the STAMPEDE Trial Collaborative Group - PLoS Medicine 2022 cited by 121

  10. PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate

    Authors: Roberta Ferraldeschi, Daniel Nava Rodrigues, Ruth Riisnaes, Susana Miranda, Ines Figueiredo, Pasquale Rescigno, Praful Ravi, Carmel Pezaro, Aurelius Omlin, David Lorente, Zafeiris Zafeiriou, Joaquı́n Mateo, Amelia Altavilla, Spyridon Sideris, Diletta Bianchini, Emily Grist, Khin Thway, Raquel Pérez-López, Nina Tunariu, Chris Parker, David P. Dearnaley, Alison Reid, Gerhardt Attard, Johann S. de Bono - European Urology 2014 cited by 258

  11. Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)

    Authors: Nicholas D. James, Noel W. Clarke, Adrian Cook, Adnan Ali, Alex Hoyle, Gerhardt Attard, Chris Brawley, Simon Chowdhury, William Cross, David P. Dearnaley, Johann S. de Bono, Carlos Díaz-Montaña, Duncan C. Gilbert, Silke Gillessen, Clare Gilson, Robert J. Jones, Ruth E. Langley, Zafar Malik, David Matheson, Robin Millman, Chris Parker, Cheryl Pugh, Hannah Rush, John M. Russell, Dominik Berthold, Michelle Buckner, Malcolm D. Mason, A.W.S. Ritchie, Alison Birtle, Susannah Brock, Prantik Das, Dan Ford, Joanna Gale, Warren Grant, Emma Gray, Peter Hoskin, Mohammad Muneeb Khan, Caroline Manetta, Neil McPhail, Joe M. O’Sullivan, Omi Parikh, Carla Perna, Carmel Pezaro, Andrew Protheroe, Angus Robinson, Sarah Maria Rudman, D.J. Sheehan, Narayanan Srihari, Isabel Syndikus, Jacob Tanguay, Carys Thomas, Salil Vengalil, John Wagstaff, James Wylie, Mahesh Parmar, Matthew R. Sydes, for the STAMPEDE Trials Collaborative Group - International Journal of Cancer 2022 cited by 77

  12. Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer

    Authors: Alex Hoyle, Adnan Ali, Nicholas D. James, Adrian Cook, Christopher Parker, Johann S. de Bono, Gerhardt Attard, Simon Chowdhury, William Cross, David P. Dearnaley, Chris Brawley, Clare Gilson, Fiona C. Ingleby, Silke Gillessen, Daniel M. Aebersold, Robert J. Jones, David Matheson, Robin Millman, Malcolm D. Mason, A.W.S. Ritchie, Martin Russell, Hassan Douis, Mahesh Parmar, Matthew R. Sydes, Noel W. Clarke - European Urology 2019 cited by 205

  13. Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer

    Authors: Adnan Ali, Alex Hoyle, Áine Haran, Chris Brawley, Adrian Cook, Claire Amos, J. Calvert, Hassan Douis, Malcolm D. Mason, David P. Dearnaley, Gerhardt Attard, Silke Gillessen, Mahesh Parmar, Christopher Parker, Matthew R. Sydes, Nicholas D. James, Noel W. Clarke - JAMA Oncology 2021 cited by 137

  14. Intermittent Androgen Suppression for Rising PSA Level After Radiotherapy

    Authors: Juanita Crook, Christopher J. O’Callaghan, Graeme Duncan, David P. Dearnaley, Celestia S. Higano, Eric M. Horwitz, Eliot Frymire, Shawn Malone, Joseph L. Chin, Abdenour Nabid, Padraig Warde, Thomas Corbett, Steve Angyalfi, S. Larry Goldenberg, Mary Gospodarowicz, Fred Saad, John Logue, Emma Hall, Paul F. Schellhammer, Keyue Ding, Laurence Klotz - New England Journal of Medicine 2012 cited by 497

  15. Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality

    Authors: Richard M. Martin, Emma L. Turner, Grace Young, Chris Metcalfe, Eleanor Walsh, J. Athene Lane, Jonathan A C Sterne, Sian Noble, Peter Holding, Yoav Ben‐Shlomo, Naomi Williams, Nora Pashayan, Mai Ngoc Bui, Peter C. Albertsen, Tyler M. Seibert, Anthony L. Zietman, Jon Oxley, Jan Adolfsson, Malcolm D. Mason, George Davey Smith, David E. Neal, Freddie C. Hamdy, Jenny Donovan, CAP Trial Group, Steven Oliver, Peter Brindle, Simon Evans, Stephen Frankel, Liz Down, Marta Tazewell, Pete Shiarly, Joanna Thorn, Sean Harrison, Luke Hounsome, Charlotte Davies, Laura Hughes, Mari‐Anne Rowlands, Lindsey Bell, Elizabeth Hill, Siaw Yein Ng, Naomi Williams, Jessica Toole, Michael Baum, Tracy Roberts, Mary Robinson, David P. Dearnaley, Fritz H. Schröder, T. J. Peters, Teresa Lennon, Sue Bonnington, Lars Holmberg, Robert Pickard, Simon G. Thompson, Usha Menon, Jon McFarlane, Richard J. Bryant, John Dormer, Colette Reid, Amit Bahl, Anthony Koupparis, David Gunnell - JAMA 2024 cited by 95

  16. NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer

    Authors: William A. Hall, E.S. Paulson, Brian J. Davis, Daniel E. Spratt, Todd M. Morgan, David P. Dearnaley, Alison Tree, Jason A. Efstathiou, Mukesh G. Harisinghani, Ashesh B. Jani, Mark K. Buyyounouski, Thomas M. Pisansky, Phuoc T. Tran, R. Jeffrey Karnes, Ronald C. Chen, Fabio Cury, Jeff M. Michalski, Seth A. Rosenthal, Bridget F. Koontz, Anthony Wong, Paul L. Nguyen, Thomas A. Hope, Felix Y. Feng, Howard M. Sandler, C.A. Lawton - International Journal of Radiation Oncology*Biology*Physics 2020 cited by 140

  17. Stereotactic body radiotherapy for oligometastases

    Authors: Alison Tree, Vincent Khoo, Rosalind A. Eeles, Merina Ahmed, David P. Dearnaley, M. Hawkins, Robert Huddart, Christopher M. Nutting, Peter Ostler, Nicholas van As - The Lancet Oncology 2012 cited by 529

  18. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial

    Authors: David P. Dearnaley, Gordana Jovic, Isabel Syndikus, Vincent Khoo, Richard Cowan, John D. Graham, Edwin Aird, David Bottomley, Robert Huddart, Chakiath Jose, J. H. Matthews, Jeremy Millar, Claire Murphy, John M. Russell, Christopher Scrase, Mahesh Parmar, Matthew R. Sydes - The Lancet Oncology 2014 cited by 462

  19. Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)

    Authors: Nicholas D. James, Melissa Spears, Noel W. Clarke, David P. Dearnaley, Johann S. de Bono, Joanna Gale, John Hetherington, Peter Hoskin, Robert J. Jones, Robert Laing, J.F. Lester, Duncan B. McLaren, Christopher Parker, Mahesh Parmar, A.W.S. Ritchie, John M. Russell, Räto T. Strebel, George N. Thalmann, Malcolm D. Mason, Matthew R. Sydes - European Urology 2014 cited by 436

  20. Magnetic resonance imaging (MRI): considerations and applications in radiotherapy treatment planning

    Authors: Vincent Khoo, David P. Dearnaley, David J. Finnigan, Anwar R. Padhani, Steven F. Tanner, Martin O. Leach - Radiotherapy and Oncology 1997 cited by 321

  21. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol

    Authors: Matthew R. Sydes, Melissa Spears, Malcolm D. Mason, Noel W. Clarke, David P. Dearnaley, Johann S. de Bono, Gerhardt Attard, S. Chowdhury, William Cross, Silke Gillessen, Zafar Malik, Robert J. Jones, Chris Parker, A.W.S. Ritchie, John M. Russell, R. Millman, David Matheson, Claire Amos, Clare Gilson, Alison Birtle, Susannah Brock, Lisa Capaldi, P. Chakraborti, Ananya Choudhury, Linda Evans, Daniel Ford, Joanna Gale, Stephanie Gibbs, Duncan C. Gilbert, Robert Hughes, Duncan B. McLaren, J.F. Lester, Ashok Nikapota, Joe M. O’Sullivan, Omi Parikh, C. Peedell, Andrew Protheroe, Sarah Maria Rudman, Richard Shaffer, Denise Sheehan, Matthew Simms, Narayanan Srihari, Raeto T. Strebel, Santhanam Sundar, Shaun Tolan, D. Tsang, M. Varughese, John Wagstaff, Mahesh Parmar, Nicholas D. James - Annals of Oncology 2018 cited by 250

  22. Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

    Authors: Gerhardt Attard, Alison Reid, Timothy A. Yap, Florence I. Raynaud, Mitch Dowsett, S. Settatree, Mary Barrett, Christopher Parker, Vanessa Martins, Elizabeth Folkerd, Jeremy Clark, Colin S. Cooper, Stan B. Kaye, David P. Dearnaley, Gloria Lee, Johann S. de Bono - Journal of Clinical Oncology 2008 cited by 896

  23. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

    Authors: Vincenza Conteduca, Daniel Wetterskog, Mansour T. A. Sharabiani, Enrique Grande, María Piedad Fernández-Pérez, Anuradha Jayaram, Samanta Salvi, Daniel Castellano, Alessandro Romanel, Cristian Lolli, Valentina Casadio, Giorgia Gurioli, D. Amadori, Albert Font, Sergio Vázquez‐Estévez, Aranzazu González del Alba, Begoña Mellado, O. Fernández-Calvo, María José Méndez-Vidal, José A. Martínez-Climent, Ignacio Durán, Enrique Gallardo, Ángel Rodríguez, Carmen Santander, M.I. Sáez, Javier Puente, Delila Gasi Tandefelt, Anna Wingate, David P. Dearnaley, Francesca Demichelis, Ugo De Giorgi, Enrique González‐Billalabeitia, Gerhardt Attard - Annals of Oncology 2017 cited by 269

  24. Microbiota and radiation-induced bowel toxicity: lessons from inflammatory bowel disease for the radiation oncologist

    Authors: Miguel Reis Ferreira, Ann Muls, David P. Dearnaley, Jervoise Andreyev - The Lancet Oncology 2014 cited by 138